Shares of RxSight, Inc. (NASDAQ:RXST – Get Free Report) have received an average recommendation of “Hold” from the ten research firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $37.90.
RXST has been the topic of a number of recent analyst reports. Piper Sandler initiated coverage on RxSight in a report on Tuesday, April 15th. They issued a “neutral” rating and a $18.00 price objective on the stock. Wells Fargo & Company upgraded shares of RxSight from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $17.00 to $25.00 in a research note on Monday, May 19th. Stifel Nicolaus dropped their price objective on shares of RxSight from $33.00 to $28.00 and set a “hold” rating on the stock in a research note on Wednesday, March 19th. Bank of America restated an “underperform” rating and issued a $22.00 price target (down from $36.00) on shares of RxSight in a research note on Thursday, April 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $43.00 price target on shares of RxSight in a research report on Thursday, April 3rd.
View Our Latest Research Report on RxSight
Institutional Trading of RxSight
RxSight Stock Performance
RxSight stock opened at $14.21 on Friday. RxSight has a 1 year low of $12.53 and a 1 year high of $60.81. The company’s fifty day moving average price is $14.86 and its 200 day moving average price is $25.68. The stock has a market capitalization of $577.45 million, a P/E ratio of -17.12 and a beta of 1.29.
RxSight (NASDAQ:RXST – Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $37.90 million for the quarter, compared to the consensus estimate of $38.74 million. During the same period in the previous year, the firm earned ($0.25) earnings per share. RxSight’s quarterly revenue was up 28.5% compared to the same quarter last year. Sell-side analysts predict that RxSight will post -0.7 EPS for the current year.
About RxSight
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Further Reading
- Five stocks we like better than RxSight
- What Are the U.K. Market Holidays? How to Invest and Trade
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- What Does Downgrade Mean in Investing?
- Alphabet Enters a Bull Market: Is It Time to Buy?
- What is the Shanghai Stock Exchange Composite Index?
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.